What the report says about Wegovy and heart risk
Semaglutide, the medicine sold as Wegovy for weight management, reduced the relative risk of major cardiovascular events by 20% in the SELECT trial, according to reporting by the Hindustan Times in India. The newspaper describes findings among people without diabetes who received the medicine for more than three years.
That figure needs careful interpretation. A 20% relative reduction does not mean that 20 out of every 100 people taking the medicine avoided a cardiovascular event. The absolute benefit depends on how often those events occurred in the comparison group; those event rates are not included in the report.
The newspaper also cites a pooled analysis involving 60,000 patients, which found a 14% relative reduction in major adverse cardiovascular events and a reported 12% reduction in deaths from any cause. Combining results across studies can give a broader assessment of a treatment, but the article does not identify the analysis or give the number of trials included.
It reports cardiovascular event reductions of 26% for semaglutide and 27% for efpeglenatide within the evidence it discusses. Those percentages alone cannot establish that one medicine is better than another: results from different studies may reflect differences in participants, follow-up and underlying risk rather than a direct comparison of treatments.
How GLP-1 medicines became part of heart research
GLP-1 receptor agonists were developed to treat diabetes. They mimic the action of a naturally occurring hormone involved in blood glucose regulation and appetite. Semaglutide is also sold as Ozempic for type 2 diabetes; the brand, dose and treatment indication matter when interpreting findings about the medicine.
The cardiovascular research programme had its roots in safety concerns. In 2008, the US Food and Drug Administration required cardiovascular outcome assessments for new diabetes medicines after concerns arose that improving blood glucose levels did not necessarily mean a treatment was safe for the heart, the Hindustan Times reports.
That distinction remains important. A change in a laboratory measurement is not the same as evidence that fewer people experience serious illness. Cardiovascular outcome trials examine clinical events rather than relying solely on blood glucose or weight changes.
The newspaper describes several possible explanations for benefits beyond weight reduction, including less inflammation, better function of blood vessels and heart muscle, more stable fatty plaques in arteries and reduced platelet clumping. These are proposed mechanisms, not a measurement of how much each process contributes to the observed benefit. Our coverage of GLP-1 medicines and inflammation examines that distinction between promising biology and clinical evidence.
What Dr Suman Banerjee says about the findings
Dr Suman Banerjee, a diabetologist quoted in the Hindustan Times article as speaking to Health Shots, describes the cardiovascular results as unexpected. His account places the original emphasis on checking safety, rather than developing diabetes treatments specifically to prevent heart problems.
The report also highlights semaglutide research in people with obesity and heart failure with preserved ejection fraction. In this condition, the heart can retain a normal proportion of blood pumped out with each beat while still failing to fill and function properly.
According to the newspaper, semaglutide improved symptom scores and the distance participants could walk in six minutes compared with placebo. It supplies neither the size of those improvements nor the study population. Those results concern symptoms and physical function; they should not be presented as equivalent to evidence of fewer deaths. They form part of the broader research into GLP-1 medicines beyond weight loss.
What remains unanswered about Wegovy’s heart benefits
The report does not announce a new prescribing policy, approval or NHS access decision. It brings together existing research, but leaves out details needed to judge how closely the participants resemble an individual considering treatment.
For that assessment, the underlying trial publications would need to establish eligibility criteria, absolute event rates, uncertainty around the estimates and adverse effects. Without those details, the reported percentages cannot provide a personal forecast of benefit or a complete benefit–risk assessment.
The article introduces the subject of head-to-head comparisons but supplies no findings from them in the available text. It therefore offers no basis for choosing between medicines on cardiovascular protection alone, or for extending semaglutide’s reported results to every weight-loss injection.
